Real-world risk factors for herpes zoster in patients with rheumatoid arthritis undergoing tofacitinib treatment
HZ is common in RA patients treated with TOFA, and recent bDMARDs (TNFi, tocilizumab, and abatacept) use is a risk factor for HZ. HZ vaccination, therefore, should be recommended for this group.
Authors
- Wei‐Sheng Chen (ORCID: https://orcid.org/0000-0001-8672-180X)
- Ming‐Tsun Tsai (ORCID: https://orcid.org/0000-0002-8597-4132)
- Chien‐Chih Lai (ORCID: https://orcid.org/0000-0002-0546-8695)
- Chih‐Yu Yang (ORCID: https://orcid.org/0000-0001-9899-3159)
- Hsien‐Tzung Liao (ORCID: https://orcid.org/0000-0001-5930-4840)
- Chang‐Youh Tsai (ORCID: https://orcid.org/0000-0002-4154-4018)
- Ming‐Han Chen (ORCID: https://orcid.org/0000-0001-7822-2613)
- Yi-Syuan Sun
- De-Feng Huang
- Hung-Cheng Tsai
Institutions
- Fu Jen Catholic University (TW)
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
Publication Details
- Journal
- Journal of the Chinese Medical Association
- Published
- 2024-08-26
- DOI
- https://doi.org/10.1097/jcma.0000000000001159
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministry of Science and Technology, Taiwan
- National Yang-Ming University
- Taipei Veterans General Hospital